BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: IMPROVEMENTS IN PSARC OVER 24 WEEKS IN THE PHASE 3 BE OPTIMAL TRIAL

被引：0
|
作者：
McInnes, Iain [1 ]
Ink, Barbara [2 ]
Bajracharya, Rajan [2 ]
Taieb, Vanessa [3 ]
Tillett, William R. [4 ]
机构：
[1] Univ Glasgow, IBM Coll Med Vet & Life Sci, Glasgow, Scotland
[2] UCB Pharma, Rheumatol, Slough, England
[3] UCB Pharma, Rheumatol, Colombes, France
[4] Univ Bath, Royal Natl Hosp Rheumat Dis, Dept Life Sci, Bath, England
来源：
RHEUMATOLOGY | 2023年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P171
引用
收藏
页数：2
相关论文
共 50 条
  • [21] EFFICACY AND SAFETY RESULTS OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 56 WEEKS
    Boehncke, Wolf Henning
    Gottlieb, Alice
    Deodhar, Atul
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 48 - 49
  • [22] Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
    Mease, Philip
    Tillett, William
    de Wit, Maarten
    Gossec, Laure
    Husni, M. Elaine
    Proft, Fabian
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Lambert, Jeremy
    Coates, Laura
    Gottlieb, Alice
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4789 - 4792
  • [23] SUSTAINED AND CONSISTENT EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF PRIOR TNF-INHIBITOR STATUS: RESULTS FROM THE PHASE 3 BE OPTIMAL AND BE COMPLETE TRIALS
    Tillett, William R.
    Ink, Barbara
    Bajracharya, Rajan
    Taieb, Vanessa
    Sharma, Poonam
    McGonagle, Dennis
    Coates, Laura C.
    McInnes, Iain B.
    RHEUMATOLOGY, 2024, 63
  • [24] Improvements in patient reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in phase IIb trial (D A N C E R)
    Mease, P
    Szechinski, J
    Greenwald, M
    Leirisalo-Repo, M
    Kivitz, A
    Barile-Fabris, L
    Kalsi, J
    Eames, J
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S138 - S139
  • [25] BIMEKIZUMAB DELIVERED SUSTAINED IMPROVEMENTS IN EFFICACY AND DEMONSTRATED A CONSISTENT SAFETY PROFILE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
    Mease, P. J.
    Merola, J. F.
    Landewe, R.
    McInnes, I. B.
    Ritchlin, C. T.
    Tanaka, Y.
    Asahina, A.
    Gossec, L.
    Ink, B.
    Heinrichs, A.
    Bajracharya, R.
    Shende, V
    Coarse, J.
    Coates, L. C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (09) : 98 - 99
  • [26] Improvements in Work Productivity with up to 104 Weeks of Apremilast Monotherapy: Results from a Phase 3b, Randomized, Controlled Study in Biologic-NaiVe Subjects with Active Psoriatic Arthritis
    Mease, Philip J.
    Gladman, Dafna D.
    Davenport, Eric K.
    Zhou, Xiaolei
    Guerette, Benoit
    Teng, Lichen
    Kaura, Satyin
    Nash, Peter
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [27] Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study
    Deodhar, Atul
    Gossec, Laure
    Mease, Philip
    Coarse, Jason
    Edens, Heather
    De Peyrecave, Natasha
    Assudani, Deepak
    Ink, Barbara
    Ritchlin, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [28] Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis
    Mease, P.
    Gladman, D.
    Davenport, E.
    Zhou, X.
    Guerette, B.
    Teng, L.
    Kaura, S.
    Nash, P.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 34 - 35
  • [29] BIMEKIZUMAB TREATMENT IN BIOLOGIC DMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY RESULTS FROM A PHASE 3, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY
    Ostor, Andrew
    Ritchlin, Christopher T.
    Coates, Laura C.
    McInnes, Iain B.
    Mease, Philip J.
    Merola, Joseph F.
    Tanaka, Yoshiya
    Asahina, Akihiko
    Gossec, Laure
    Gottlieb, Alice B.
    Thaci, Diamant
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Shende, Vishvesh
    Coarse, Jason
    Landewe, Robert
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 26 - 26
  • [30] Bimekizumab Treatment in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
    Ritchlin, Christopher
    Coates, Laura
    McInnes, Iain
    Mease, Philip J.
    Merola, Joseph
    Tanaka, Yoshiya
    Asahina, Akihiko
    Gossec, Laure
    Gottlieb, Alice
    Thaci, Diamant
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Shende, Vish
    Coarse, Jason
    Landewe, Robert
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4533 - 4536
12345